Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
LLY Eli Lilly and Co
371.790
-0.180-0.05%
Post Mkt Price
371.7900.0000.00%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Total revenue
2.49% 6.94B -3.74% 6.49B 14.76% 7.81B 15.40% 28.32B
Operating revenue
2.49% 6.94B -3.74% 6.49B 14.76% 7.81B 15.40% 28.32B
Cost of revenue
10.36% 1.58B -26.76% 1.43B 10.30% 2.07B 33.36% 7.31B
Gross profit
0.38% 5.36B 5.65% 5.06B 16.46% 5.74B 10.23% 21.01B
Operating expense
3.96% 3.42B 1.44% 3.41B -2.85% 3.17B 10.25% 13.46B
Selling and administrative expenses
2.30% 1.61B -3.59% 1.63B -1.15% 1.56B 5.07% 6.43B
Research and development costs
5.50% 1.8B 6.52% 1.78B -4.43% 1.61B 15.45% 7.03B
Operating profit
-5.34% 1.95B 15.55% 1.65B 54.24% 2.57B 10.20% 7.55B
Net non-operating interest income expense
19.84% -61.4M 12.88% -71M 5.35% -77.9M 3.74% -314.4M
Non-operating interest income
187.14% 20.1M 88.89% 10.2M 27.27% 7M -23.03% 25.4M
Non-operating interest expense
-2.51% 81.5M -6.56% 81.2M -3.30% 84.9M -5.51% 339.8M
Other net income (expense)
56.57% -318.5M -297.81% -488.6M -307.81% -438.4M -252.53% -1.08B
Gain on sale of security
50.04% -123.3M -155.20% -118.9M -241.09% -425.4M -- 176.9M
Special income (charges)
53.57% -268.9M -1,661.60% -440.4M 67.59% -165.6M -101.64% -1.6B
-Less:Restructuring and merger&acquisition
-- 0 -- 0 -- 0 -- 13M
-Less:Other special charges
-89.23% 62.4M 1,661.60% 440.4M -44.67% 165.6M 93.84% 1.28B
-Write off
-- 206.5M -- 0 -- 0 -- 303.1M
-Gain on sale of business
-- -- -- -- -- -- -- 0
Other non- operating income (expenses)
-20.50% 73.7M 24.91% 70.7M 49.75% 152.6M -77.24% 341.1M
Income before tax
25.71% 1.57B -31.56% 1.09B 39.10% 2.05B -14.86% 6.16B
Income tax
-15.83% 113.8M -32.06% 138.4M 24.44% 150.7M -44.62% 573.8M
Net income
30.77% 1.45B -31.48% 952.5M 40.40% 1.9B -9.88% 5.58B
Net income continuous Operations
30.77% 1.45B -31.48% 952.5M 40.40% 1.9B -9.88% 5.58B
Net income discontinuous operations
-- -- -- -- -- -- -- 0
Minority interest income
Net income attributable to the parent company
30.77% 1.45B -31.48% 952.5M 40.40% 1.9B -9.88% 5.58B
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
30.77% 1.45B -31.48% 952.5M 40.40% 1.9B -9.88% 5.58B
Basic earnings per share
31.97% 1.61 -30.72% 1.06 41.61% 2.11 -9.82% 6.15
Diluted earnings per share
31.97% 1.61 -31.37% 1.05 40.94% 2.1 -9.87% 6.12
Dividend per share
15.29% 0.98 15.29% 0.98 15.29% 0.98 14.86% 3.4
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
------Unqualified Opinion

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm's products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity. The Oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. The Immunology products include Olumiant and Taltz. The Neuroscience products consist of Cymbalta, Emgality, Reyvow, and Zyprexa. The Other therapies include Bamlanivimab, Cialis, and Forteo. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
CEO: Mr. David A. Ricks
Market: NYSE
Listing Date: 04/01/1973
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist